CutisPharma appoints new CEO

CutisPharma, a specialty pharmaceutical company, yesterday named President Neal Muni as the company’s new CEO.

Neal Muni is taking the place of Indu Muni, founder of CutisPharma. Indu Muni will remain chairman of the board of directors.

"I am proud of the accomplishments we have made during my 17 years leading CutisPharma," Indu Muni said. "From our humble beginnings in 1998, starting with just a concept and vision, the company has grown into the well-established industry leader. I believe that Neal Muni's background and expertise make him the right person to lead CutisPharma through the next phase of its growth plan."

Neal Muni has served as president since July. During his time as president he led the development and implementation of multiple operational and commercial projects.

"I am excited to build on CutisPharma's impressive growth trajectory and to lead the company as it pursues its long-term strategic vision of transforming compounding through innovation," Neal Muni said. "There are significant needs for high quality and solid science in pharmaceutical compounding, and our company's mission over its 17 years of operation has been to provide patients with better solutions based first and foremost on quality."

Neal Muni previously served as the executive director of new product planning at Sunovion Pharmaceuticals. Currently, he keeps staff appointments with the Department of Medicine at Brigham and Women's Hospital and is an instructor of medicine at Harvard Medical School.